StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biotechnology company's stock.
CALA has been the topic of several other research reports. LADENBURG THALM/SH SH lowered shares of Calithera Biosciences from a buy rating to a neutral rating in a research report on Tuesday, November 15th. SVB Leerink lowered shares of Calithera Biosciences from an outperform rating to a market perform rating in a research report on Tuesday, November 15th.
Get Calithera Biosciences alerts:Calithera Biosciences Stock Performance
CALA stock opened at $0.05 on Friday. The firm has a market cap of $258,110.00, a PE ratio of 0.00 and a beta of 1.22. The firm's fifty day moving average is $0.42 and its 200 day moving average is $1.88. Calithera Biosciences has a one year low of $0.05 and a one year high of $13.38.
Insider Activity
In other news, Director Deepika Pakianathan sold 121,333 shares of Calithera Biosciences stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $0.39, for a total value of $47,319.87. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.60% of the company's stock.
Institutional Trading of Calithera Biosciences
Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its position in shares of Calithera Biosciences by 36.5% in the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock valued at $749,000 after purchasing an additional 496,100 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Calithera Biosciences in the first quarter worth about $404,000. Affinity Asset Advisors LLC purchased a new position in shares of Calithera Biosciences in the first quarter worth about $404,000. Vanguard Group Inc. lifted its stake in shares of Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after buying an additional 26,800 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after buying an additional 72,865 shares in the last quarter. Institutional investors and hedge funds own 33.73% of the company's stock.
About Calithera Biosciences
(Get Rating)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Featured Articles
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.